Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Urol. 2017 May 4;199(1):43–52. doi: 10.1016/j.juro.2017.04.092

Figure 1.

Figure 1

Current landscape of risk stratification and adjuvant trials for high-risk localized kidney cancer. TNM, tumor node metastasis classification; UISS, University of California Los Angeles Integrated Staging System; MSK, Memorial Sloan Kettering; SSIGN, stage size grade necrosis; IFN-α, interferon-α; HD IL-2, high-dose interleukin-2; VEGF, vascular endothelial growth factor; mTOR, mammalian target of rapamycin; ADCC, antibody-dependent cellular cytotoxic; CAIX, carbonic anhydrase IX.